Better Early Than Late: CDK4/6 Inhibition in HR +, HER2- Early Breast Cancer
b'Host: Hope S. Rugo, MD, FASCO
\\n\\n Guest: Peter Schmid, FRCP, MD, PhD
\\n\\n\\n \\n
HR+/HER2- breast cancer accounts for approximately 70% of early breast cancer. Now that the CDK4/6 inhibitor abemaciclib has been approved in the United States and internationally for the treatment of HR+/HER2- early breast cancer, it\\u2019s important to keep up with the latest data for its use. Listen in so Drs. Hope Rugo and Peter Schmid can keep you up to date on the most effective ways to treat your patients.
'